Skip to main content

Table 5 Uni- and multivariate Cox proportional hazards regression survival analysis

From: The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer

  

Univariate model DFS

Multivariate model DFS

Univariate model OS

Multivariate model OS

Parameters

n

HR

(95% CI)

P

HR

(95% CI)

P

HR

(95% CI)

P

HR

(95% CI)

P

 

279

                

Age at primary surgery

    

0.25

   

0.31

   

0.19

   

0.18

  ≤ 40 years

29

1

   

1

   

1

   

1

   

 41–50 years

81

0.59

0.35

1.00

0.049

0.60

0.35

1.02

0.06

0.53

0.30

0.96

0.036

0.51

0.28

0.94

0.032

 51–70 years

125

0.73

0.44

1.19

0.20

0.72

0.44

1.18

0.19

0.75

0.44

1.28

0.30

0.72

0.42

1.26

0.25

  > 70 years

44

0.78

0.43

1.40

0.41

0.71

0.39

1.28

0.25

0.73

0.37

1.43

0.35

0.73

0.37

1.47

0.38

Menopausal status

                 

 Premenopausal

120

1

       

1

       

 Postmenopausal

159

1.01

0.73

1.38

0.96

    

1.06

0.74

1.53

0.73

    

Pathological Tumor classification

    

0.009

   

0.037

   

0.017

   

0.019

 pT1

151

1

   

1

   

1

   

1

   

 pT2 + unknown

119

1.54

1.12

2.11

0.007

1.35

0.98

1.88

0.069

1.30

0.90

1.87

0.165

1.19

0.81

1.74

0.375

 pT3 + pT4

9

2.31

1.00

5.32

0.049

2.47

1.07

5.75

0.035

3.26

1.39

7.62

0.006

3.45

1.45

8.19

0.005

Grade

    

 < 0.001

   

0.001

   

0.033

   

0.082

 poor

131

1

   

1

   

1

   

1

   

 unknown

81

1.36

0.97

1.91

0.076

1.40

0.98

1.99

0.064

0.89

0.59

1.34

0.577

0.97

0.64

1.48

0.894

 moderate and good

67

0.52

0.33

0.82

0.004

0.57

0.36

0.89

0.014

0.51

0.31

0.85

0.009

0.57

0.34

0.94

0.029

ER

279

1.11

0.98

1.25

0.10

    

0.99

0.86

1.14

0.92

    

PR

                 

 negative

62

1

   

1

   

1

   

1

   

 positive

217

0.66

0.46

0.93

0.019

0.68

0.47

0.98

0.037

0.49

0.33

0.73

 < 0.001

0.56

0.37

0.85

0.007

HER2 statusa

                 

 not amplified

233

1

       

1

   

1

   

 amplified

43

1.21

0.80

1.84

0.36

    

1.82

1.17

2.84

0.008

1.72

1.08

2.73

0.022

  

Univariate model PFS

 

Univariate model post-relapse survival

 

1st line Tamoxifen

235

          

 at least one ESR1-CCDC170 (exon 2 to 8) fusion

 

0.96

0.71

1.30

0.81

 

1.16

0.85

1.60

0.35

 

 ESR1-AKAP12

 

1.37

0.61

3.10

0.44

 

1.92

0.84

4.35

0.12

 

1st line AI

87

          

 at least one ESR1-CCDC170 (exon 2 to 8) fusion

 

0.85

0.53

1.37

0.50

      

 ESR1-AKAP12

 

1.62

0.73

3.60

0.24

      
      

Separately added to the base model

     
  

Univariate model DFS

Multivariate model DFS

Univariate model OS

Multivariate model OS

at least one ESR1-CCDC170 (exon 2 to 8) fusion

                 

 negative

213

1

   

1

   

1

   

1

   

 positive

66

1.44

1.01

2.05

0.044

1.33

0.92

1.92

0.13

1.67

1.13

2.47

0.010

1.54

1.02

2.33

0.042

ESR1-CCDC170 (exon 2) fusion

                 

 negative

246

1

       

1

   

1

   

 positive

33

1.40

0.89

2.21

0.14

    

1.75

1.07

2.87

0.026

1.38

0.82

2.33

0.22

ESR1-CCDC170 (exon 8) fusion

                 

 negative

240

1

   

1

   

1

   

1

   

 positive

39

1.95

1.30

2.93

0.001

1.82

1.20

2.75

0.005

1.85

1.18

2.90

0.007

1.71

1.08

2.72

0.023

ESR1-AKAP12

                 

 negative

274

1

       

1

       

 positive

5

1.23

0.39

3.87

0.72

    

2.45

0.90

6.65

0.08

    
  1. DFS disease free survival, OS overall survival, HR hazard ratio, CI interval of confidence, pT1 small primary tumor (tumour is 2 cm across or less), pT2 tumour more than 2 cm but no more than 5 cm across, pT3 T3 tumour bigger than 5 cm across pT4 tumor with phatological stage, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor, AI aromatase inhibitors, ESR1-CCDC170 ESR1-CCDC170 gene fusion, ESR1-AKAP12 ESR1-AKAP12 gene fusion. Statistically significant differences are indicated in bold
  2. a due to unknown data numbers do not add up to 279
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us